Zobrazeno 1 - 10
of 429
pro vyhledávání: '"Thomas E. Hutson"'
Publikováno v:
BMC Health Services Research, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Introduction The majority of metastatic renal cell carcinoma (mRCC) patients receive one or more VEGFR TKI agents, alone or in combination with an immune-oncology (IO) agent or an mTOR inhibitor. To date, the cost of adverse events (AEs) com
Externí odkaz:
https://doaj.org/article/8ef7bbd24a304d5b9b93e0aceb84d027
Autor:
Viktor Grünwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert Motzer, Thomas E. Hutson, María José Méndez-Vidal, Sung-Hoo Hong, Eric Winquist, Jeffrey C. Goh, Pablo Maroto, Tomas Buchler, Toshio Takagi, Joseph E. Burgents, Rodolfo Perini, Cixin He, Chinyere E. Okpara, Jodi McKenzie, Toni K. Choueiri
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
Externí odkaz:
https://doaj.org/article/3d4ee96893544a25bb56c9e784f1f819
Autor:
Viktor Grünwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert Motzer, Thomas E. Hutson, María José Méndez-Vidal, Sung-Hoo Hong, Eric Winquist, Jeffrey C. Goh, Pablo Maroto, Tomas Buchler, Toshio Takagi, Joseph E. Burgents, Rodolfo Perini, Cixin He, Chinyere E. Okpara, Jodi McKenzie, Toni K. Choueiri
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionThe phase 3 CLEAR study demonstrated that lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (RCC). Prognostic features including presence
Externí odkaz:
https://doaj.org/article/09be4e69130a41858b234cdb2b5887cc
Autor:
Scott S Tykodi, Daniel J George, Jeff Yorio, Lucio N Gordan, Joshua Zhang, Jennifer L Johansen, Arash Rezazadeh Kalebasty, David R Spigel, Samith T Kochuparambil, Ana M Molina, Heidi McKean, Nishan Tchekmedyian, Margarita Askelson, Thomas E Hutson
Publikováno v:
BMJ Open, Vol 12, Iss 9 (2022)
Objectives The non-randomised, open-label, phase IIIb/IV multicohort CheckMate 920 trial explored the safety and efficacy with a less frequent, but continual nivolumab plus ipilimumab (NIVO+IPI) dosing regimen (cohort 1) to determine whether this mod
Externí odkaz:
https://doaj.org/article/a35e5923581b4b07b7b03b97b3b2d842
Autor:
Halbert, Ronald J., Figlin, Robert A., Atkins, Michael B., Bernal, Myriam, Hutson, Thomas E., Uzzo, Robert G., Bukowski, Ronald M., Khan, Khuda Dad, Wood, Christopher G., Dubois, Robert W.
Publikováno v:
Cancer; November 2006, Vol. 107 Issue: 10 p2375-2383, 9p
Autor:
Zeynep B. Zengin, Sumanta K. Pal, David F. McDermott, Bernard Escudier, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael B. Atkins, Vijay Kasturi, Brian Rini
Publikováno v:
Clinical Genitourinary Cancer. 20:553-557
Tivozanib, vascular endothelial growth factor receptor inhibitor, met the primary endpoint of improved progression free survival compared to sorafenib in the phase 3 TIVO-3 study in patients with previously treated metastatic renal cell carcinoma. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5068282411b44306ea0b588c661ca173
https://doi.org/10.1016/j.clgc.2022.08.005
https://doi.org/10.1016/j.clgc.2022.08.005
Autor:
Sabina Signoretti, Lini Pandite, Yuan Liu, Christopher Carpenter, Katherine L. Baker-Neblett, Thomas E. Hutson, Jonathan E. Rosenberg, Victoria Brown, Brittany Bahamon, Ying Lin, Robert Gagnon, André P. Fay, Toni K. Choueiri
Purpose: Inactivation of von Hippel-Lindau (VHL) gene in clear-cell renal cell carcinoma (RCC) leads to increased levels of hypoxia-inducible factors (HIF) and overexpression of HIF target genes, such as VEGF and others. VEGF-targeted agents are stan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b03e5f798ca0ef8f6c742103614e4d96
https://doi.org/10.1158/1078-0432.c.6522240
https://doi.org/10.1158/1078-0432.c.6522240
Autor:
Robert Motzer, Saby George, Jaime R Merchan, Thomas E Hutson, Xun Song, Rodolfo F Perini, Ran Xie, Urmi Bapat, Javier Puente
Publikováno v:
The Oncologist.
BackgroundLenvatinib plus pembrolizumab showed significantly improved progression-free and overall survival outcomes compared with sunitinib in patients with advanced renal cell carcinoma in the CLEAR study (NCT02811861). Here, we used CLEAR data to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60c9e3f831dcae11a85027550854f15e
https://doi.org/10.1093/oncolo/oyac269
https://doi.org/10.1093/oncolo/oyac269
Autor:
Bradford R Hirsch, John M Burke, Manish Agrawal, Ralph J Hauke, Thomas E Hutson, Gury Doshi, Mark T Fleming, Nicholas J Vogelzang
Publikováno v:
Journal of Kidney Cancer and VHL, Vol 3, Iss 1, Pp 23-35 (2016)
The treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past decade. As the number of available agents, and related volume of research, has grown, it is increasingly complex to know how to optimally treat patients. The
Externí odkaz:
https://doaj.org/article/d0df7e06ded845189cfe1511e28aaeab
Autor:
Bradley Curtis Carthon, Jesus Zoco, Thomas E. Hutson, Mark R. Olsen, Edward Arrowsmith, Johanna C. Bendell, Hamid Emamekhoo, Joshua Zhang, Daniel J. George, Scott S. Tykodi, David Leung, Ana M. Molina, Alexandra Drakaki, Lucio N. Gordan, Ivor John Percent, Daniel C. Cho, Jennifer L. Johansen, Arash Rezazadeh Kalebasty
Publikováno v:
Cancer. 128:966-974
Background Nivolumab plus ipilimumab (NIVO + IPI) has demonstrated long-term efficacy and safety in patients with previously untreated, advanced renal cell carcinoma (aRCC). Although most phase 3 clinical trials exclude patients with brain metastases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47447a8d84cc5d3bc187e0281ee97bfe
https://doi.org/10.1002/cncr.34016
https://doi.org/10.1002/cncr.34016